HemoSep technology reduces blood loss in open-heart surgery procedures
HemoSep, a surgical blood salvage technology developed at the University of Strathclyde, Glasgow, and licensed to Advancis Surgical, has been touted by its developers as offering the potential to transform the way major surgery is carried out by reducing blood loss in patients. The device has gained the CE mark and Canadian national approval following clinical trials at the University of Kirikkale University Hospital in Ankara, Turkey.
The device consists of a blood bag, which employs a chemical sponge technology and a mechanical agitator to concentrate blood sucked from the surgical site or drained from the heart-lung machine after the surgery. The separated cells are then returned to the patient by intravenous transfusion. Professor Terry Gourlay, who led the development of the technology at the University's Department of Biomedical Engineering, believes the introduction of HemoSep will make a significant difference to people's lives and greatly reduce the cost and risks associated with blood transfusions. The technology is said to have distinct advantages over traditional techniques which are costly, technically challenging and involve the use of a complex centrifuge and pumping apparatus.